Por favor, use este identificador para citar o enlazar este ítem: 10.1039/D2FO00552B

Registro completo de metadatos
Campo DCValorLengua/Idioma
dc.contributor.authorRomo Vaquero, María-
dc.contributor.authorFernández Villalba, Emiliano-
dc.contributor.authorGil Martínez, Ana Luisa-
dc.contributor.authorCuenca Bermejo, Lorena-
dc.contributor.authorEspín de Gea, Juan Carlos-
dc.contributor.authorHerrero Ezquerro, María Trinidad-
dc.contributor.authorSelma García, María Victoria-
dc.date.accessioned2024-02-09T11:14:49Z-
dc.date.available2024-02-09T11:14:49Z-
dc.date.issued2022-04-28-
dc.identifier.citationFood Funct., 2022, 13, 6306-6316es
dc.identifier.urihttp://hdl.handle.net/10201/139090-
dc.descriptionOpen Access Article This Open Access Article is licensed under a Creative Commons Attribution-Non Commercial 3.0 Unported Licencees
dc.description.abstractGut microbiota alteration (gut dysbiosis) occurs during the onset and progression of Parkinson's disease. Gut dysbiosis biomarkers could be relevant to prodromal disease. Urolithins, anti-inflammatory metabolites produced from some dietary polyphenols by specific gut microbial ecologies (urolithin metabotypes), have been proposed as biomarkers of gut microbiota composition and functionality. However, this has not been explored in Parkinson's disease patients. The current study aimed to assess associations between urolithin metabotypes, gut dysbiosis and disease severity in Parkinson's disease patients. Participants (52 patients and 117 healthy controls) provided stool samples for microbiota sequencing and urine samples for urolithin profiling before and after consuming 30 g of walnuts for three days. Data on demographics, medication, disease duration and Hoehn and Yahr disease stage were collected. We observed a significant gradual increase of urolithin non-producers (metabotype-0) as the disease severity increased. The gut microbiome of metabotype-0 patients and patients with the greatest severity was characterized by a more altered bacterial composition, i.e., increased pro-inflammatory Enterobacteriaceae and reduced protective bacteria against autoimmune and inflammatory processes, including butyrate and urolithin-producing bacteria (Lachnospiraceae members and Gordonibacter). Besides, their microbiome was characterized by predictive functions of lipopolysaccharide biosynthesis and metabolism of glutathione, cysteine and methionine that could indirectly reflect the gut pro-inflammatory status. Urolithin detection in urine is a feasible, non-invasive and fast approach that can reflect gut microbiome dysbiosis and intestinal inflammation in Parkinson's disease patients. Our current study could provide novel strategies for improving diagnostics, and for preventing and treating disease progression in microbiota-based interventions.es
dc.formatapplication/pdfes
dc.format.extent11es
dc.languageenges
dc.publisherThe Royal Society of Chemistryes
dc.relationThis research has been supported by the projects AGL2015-64124-R and PID2019-103914RB-I00 (Spanish Ministry of Science and Innovation), PIE-201570I005 (Spanish National Research Council) and FS/20880/PI/18 (Fundación Séneca, Spain). The authors are grateful to the Murcia Federation of Parkinson's disease, Victoria López, Marian Martín, Genoveva Órtiz, and Consuelo Sánchez Rodrigo for their help and support during the study.es
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectParkinson's Diseasees
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicinaes
dc.titleUrolithins: potential biomarkers of gut dysbiosis and disease stage in Parkinson's patientses
dc.typeinfo:eu-repo/semantics/articlees
dc.relation.publisherversionhttps://pubs.rsc.org/en/content/articlehtml/2022/fo/d2fo00552bes
dc.identifier.doi10.1039/D2FO00552B-
dc.contributor.departmentDepartamento de Anatomía Humana y Psicobiología-
Aparece en las colecciones:Artículos

Ficheros en este ítem:
Fichero Descripción TamañoFormato 
2022 Urolithins- potential biomarkers of gut dysbiosis and disease stage in Parkinson’s patients.pdf4,45 MBAdobe PDFVista previa
Visualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons